Hemosiderosis clinical trials
The registry lists 14 studies for Hemosiderosis across more than 10 countries. 1 are recruiting or about to start. 3 of them are mainly about Hemosiderosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-04-27.
Get an email when these change. Save the Hemosiderosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (4) · University of Wisconsin, Madison (2) · Novartis (1) · Assistance Publique - Hôpitaux de Paris (1) · Seoul National University Hospital (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Centre Hospitalier Sud Francilien (1) · ApoPharma (1)
What is being tested here
Drugs under test in Hemosiderosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Deferasirox | 0 | 3 | 6 |
| Deferiprone | 0 | 0 | 1 |
| Deferoxamine | 0 | 0 | 1 |
Drug classes tested here Iron chelators 7
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Aug 2027Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation. · Assistance Publique - Hôpitaux de Paris
Who these studies take
Of the 1 Hemosiderosis studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 14 studies, recruiting or not: 36% stop at 75 or younger and 29% at 65; 79% take children; 0% are for women only and 0% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 14 of 14. search them.
- Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.RecruitingNCT070281121 country
- Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron ContentCompletedNCT020255431 country
- Infectious and Non-infectious Lower Respiratory Diseases in Children With Down Syndrome Followed in Pediatric Pulmonology Consultations in Ile-de-FranceCompletedNCT063365771 country
- The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric PatientsTerminatedNCT042843711 country
- Non-invasive Quantification of Liver Iron With MRICompletedNCT015168531 country
- A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.Status unknownNCT019356611 country
- Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00067080Phase 21 country
- A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisCompletedNCT00171171Phase 35 countries
- Safety, Tolerability, and Efficacy of Deferasirox in MDSCompletedNCT00469560Phase 31 country
- Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 42 countries
- Pharmacogenetic Study in Patients Received Iron Chelating AgentCompletedNCT016238951 country
- Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00061750Phase 31 country
- Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 45 countries
- Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 27 countries